Abivax |
abivax.com
Actively hiring
Immunology & Inflammation Therapeutics
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
20–49
French register · Dec 2023
Backers
1
Sofinnova Partners
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Registers and programsofficial lists and records that name the company
| Legal entity | ABIVAX | recherche-entreprises |
| Registered | 4 Dec 2013 |
Founders and leadersfrom filings, registers and the company's site
Marc De Garidel-ThoronDirecteur Généralcompany register
Sylvie GregoirePrésident du conseil d’administrationcompany register
Backed byfrom the funds' portfolios and accelerator catalogs
Sofinnova Partners Similar startupsby what they do, their industry and backers
Quell Therapeutics is a clinical-stage company, fuelled by curiosity and discovery, on a mission to make life better for those battling…
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation biologics for severe immune-mediated inflammatory…
Coultreon Biopharma is a clinical-stage biotech company developing next-generation precision medicines for immunology and autoimmune…
SFA Therapeutics is developing a next-generation oral immune tolerance therapy for psoriasis. Our investigational approach is designed to…
CAMPfield Therapeutics is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor…
Decoding Human T issue Biology to C reate Revolutionary T herapeutics. TRexBio is developing immunoregulatory medicines designed to restore…
News
ABIVAX (ABVX) Uses More Cash. Can its Funding Cover a Potential Launch?
ABIVAX Société Anonyme (NASDAQ:ABVX) reported first-half 2026 operating cash use of €102.5 million on September 21, up from €66.6 million a year earlier. The roughly 54% increase highlights the growing cost of advancing obefazimod while preparing for pote
Read more
Report
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX) and Eli Lilly & Co (LLY)
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Read more
Report
Abivax Extends Cash Runway Into Q4 2029 Following $920 Million Offering And Announces Leadership Changes
Abivax, a clinical-stage biotechnology company developing treatments for chronic inflammatory diseases, reported its first-half 2026 financial results and announced several leadership changes as it prepares for the potential commercialization of obefazimo
Read more
Report
Abivax H1 Net Loss Widens; Plans Obefazimod NDA For Ulcerative Colitis By End Of 2026
Abivax SA (ABVX, ABVX.PA), a clinical-stage biotechnology company, reported first-half 2026 financial results, reflecting a wider net loss, and provided an update on near-term milestones.
Read more
Report
Pro access
Upgrade to see all 12 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
People
Marc De Garidel-Thoron
Directeur Général
Sylvie Gregoire
Président du conseil d’administration
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Paris
France
HQ
NOW ESTABLISHED IN EUROPE AND THE US
10-50 est. staff
7-11 Boulevard Haussmann 75009 Paris, France